[FRIAM] is this true?

[glen ∅]

Excellent!  Thanks.

The stuff I've found so far seems a bit motivated.  For example, this article:

https://www.nytimes.com/2002/08/27/health/behavior-like-drugs-talk-therapy-can-change-brain-chemistry.html

Talks about functional reduction of activity in brain regions (one for OCD and a different region for depression), where either the drug or the therapy were used.  I couldn't find the original studies, but haven't looked very hard.  The thing that worries me is the way they worded this article.  Did they only saw the basic brain activity change in those patients who responded?  If so, it seems like the result is baked into the experiment to some extent.  I'm left wondering how/if the drug and therapy changed the brains of the non-responders.  Did the drugs and talk therapies change the brains of the non-responders in similar ways?  Or is the only similarity in these 2 cases *that* the responders exhibited similar changes?

This article was more circumspect, I think:

Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline
https://www.nature.com/articles/s41398-018-0128-4

"These observations suggest that, for some patients, successful remediation of OCD symptoms might be associated with greater serotonergic tone."

I suppose the idea being any intervention that modifies seratonergic tone (drugs, talk, whatever) may be viable.

This article helps justify my worry that the brain changes in non-responders aren't considered:

A RANDOMIZED, CONTROLLED TRIAL OF MEDICATION AND COGNITIVE BEHAVIOR THERAPY FOR HYPOCHONDRIASIS
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957509/

"This study supports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis. Joint treatment provided a small incremental benefit. Because approximately 50% of patients did not respond to the study treatments, new or more intensive approaches are needed."



On 3/8/19 7:11 AM, Frank Wimberly wrote:
> Also articles like this:  https://www.sciencedirect.com/science/article/abs/pii/0010440X74900467
> 
> On Fri, Mar 8, 2019 at 7:41 AM Frank Wimberly <wimberly3 at gmail.com <mailto:wimberly3 at gmail.com>> wrote:
> 
>     I am using pice to text for this so there will be errors.
> 
>     dysregulation with Central mono and energy systems is believed to underlie the pathology of depression. Drugs that selectively inhibit the reuptake of central monoamines have been used clinically to alleviate symptoms of depressive illness Duloxetine a novel compound currently under investigation for the treatment of depression buying selectively with high affinity to both norepinephrine and serotonin transporters and lacs affinity for Mon Ami receptors within the central nervous system it has been suggested that dual inhibition of Moana ome reuptake processes may offer advantages over other antidepressants currently in use in preclinical studies Duloxetine mimics many physiologic effects of antidepressants consistent with other antidepressants Duloxetine by a cute administration elevates extracellular how do I have any levels well by chronic administration is does not it does not
> 
>     Duloxetine has brand name Cymbalta.
> 
>     Maybe you could search for does psychotherapy do....  ?
> 
-------------- next part --------------
A non-text attachment was scrubbed...
Name: pEpkey.asc
Type: application/pgp-keys
Size: 2448 bytes
Desc: not available
URL: <http://redfish.com/pipermail/friam_redfish.com/attachments/20190308/a346d6b3/attachment.bin>